Marksans Pharma Share Price Target 2025, 2026, 2028, 2030, 2040

Marksans Pharma Share is in a bullish trend in the share market. During share ups and downs, you should know all about the share details before investing. In this blog, we are going to discuss the Marksans Pharma Share Price Target 2025, 2026, 2028, 2030, and 2035. We will try to analyze the share base in the company’s overall performance.

We also look at the company’s profit growth in the last 5 years, the last 5 years’ sales growth, and the last 5 years’ ROE percentage. Similarly, we also compare the share growth, the share price return, amount whether the share has increased or decreased over the last 5 years. We also take advice from experts about when we should invest in the share, which may be helpful for you. Let’s have a look at the Marksans Pharma Share Price Target from 2025 to 2035.

Overview Of Marksans Pharma Limited

Marksans Pharma Limited is a wholly owned subsidiary of Time-Cap Laboratories, Inc., has received an Establishment Inspection Report (EIR) from the US Food & Drug Administration for the audit conducted in October 2023. The company has received USFDA approval for Guaifenesin Extended-Release Tablets

Fundamental Analysis Of Marksans Pharma Limited

Company Name	Marksans Pharma Limited
Market Cap	₹11,140.68 Crore
Book Value	₹31.36
Face Value	₹1
P/B	8.62
P/E	60.24
52 Week High	₹359.32
52 Week Low	₹130.15
DIV. YIELD	0.33%
ROE	11.48%

Last Few Years’ Performance Of Marksans Pharma Limited

Profit Growth

• In the last 5 years, 26.01%
• In the last 3 years, 11.37%
• In the last 1 year, 30.59%

The Net Profit of the company was ₹103.29 Crore in March 2023, which increased to ₹134.25 Crore in March 2024. The Operating Profit of the company was ₹73.12 Crore in March 2023, which increased to ₹140.39 Crore in March 2024.

Sales Growth

The sales growth percentage of the company in the last 5 years is described below.

• In the last 5 years, 16%
• In the last 3 years, 13.26%
• In the last year, 30.68%

The Net Sales amount of the company was ₹657.23 Crore in March 2023, which decreased to ₹854.69 Crore in March 2024.

ROE Percentage

The ROE percentage growth of the company in the last 5 years is described below.

• In the last 5 years, 12.92%
• In the last 3 years, 12.98%
• In the last 1 year, 11.68%

ROCE Percentage

The company’s ROCE percentage growth in the last 5 years is described below, and it has also increased rapidly.

• In the last 5 years, 16.95%
• In the last 3 years, 16.34%
• In the last 1 year, 14.82%

Total Expenditure Amount

The company’s Total Expenditure was ₹584.36 Crore in March 2023, increasing to ₹714.29 Crore in March 2024.

The Net Cash Flow Amount

The Net Cash Flow amount of the company was ₹67.52 Crore in March 2023, which decreased to -₹107.26 Crore in March 2024.

Marksans Pharma Share Price Target 2025

Marksans Pharma Share Price Target forecast for 2025 may vary from ₹223.02 to ₹272.68.

Influencing Key Factors For Marksans Pharma Share Price Target 2025

• Mission Of Marksans Pharma Limited Company
• Marksans Pharma is a customer-centric pharmaceutical company committed to delivering drugs that cater to consumers’ specific needs. The company is one of the leading pharmaceutical companies with a strong foothold in highly regulated markets, specializing in OTC and prescription (Rx) drugs.
• Manufacturing Units
• The company has manufacturing units in Goa (India), Farmingdale (United States), and Southport (UK). In Goa, manufacturers make capsules and tablets. One of the biggest manufacturing facilities in Asia is a fully automated unit spread over an 18,000-square-meter campus. Generic pharmaceuticals manufactured at this facility are exported across the globe. The company has a manufacturing capacity of 2.4 billion softgel and hard gelatin capsules per annum and 6 billion solid tablets per annum from this manufacturing segment.

Month	Marksans Pharma Share Price Target 2025 (1st Price Target)	Marksans Pharma Share Price Target 2025 (2nd Price target)
May	₹223.02	₹250.36
June	₹247.52	₹255.19
July	₹253.94	₹262.35
August	₹260.72	₹269.80
September	₹267.91	₹273.66
October	₹270.30	₹275.24
November	₹268.72	₹275.90
December	₹263.51	₹272.68

Also Read – Divis Lab Share Price Target

Marksans Pharma Share Price Target 2026

Marksans Pharma Share Price Target forecast for 2026 may vary from ₹270.16 to ₹316.64.

Influencing Key Factors For Marksans Pharma Share Price Target 2026

• Manufacturing Facilities In Farmingdale, United States
• In these manufacturing units, the company manufactures tablets and capsules, which are spread over an area of 7000 square meters. This unit of manufacturing added incremental packaging lines. From these segments of manufacturing, 6 billion tablets and hard capsules per annum are manufactured.
• Innovating For Tomorrow
• The company’s presence extends to more than 10 therapeutic areas, OTC products for pain management, cough and cold, digestive, vitamins, supplements, and anti-allergic medications. The company has over 50 FDA-approved products and provides over 100 products in the UK under the Bells Healthcare Brand and over 160 products under the Relonchem brand. The company also offers over 30 products in Australia.
• USFDA Approval For Pregabalin Capsules
• The company has an achievement from the US Food and Drug Administration (FDA), granting final approval for the company’s Abbreviated New Drug Application (ANDA) for pregabalin capsules. This approval encompasses a wide range of dosage strengths, from 25 mg to 300 mg. These Pregabalin Capsules have been rigorously tested and proven to be both bioequivalent and therapeutically equivalent to the renowned reference-listed drug (RLD), Lyrica Capsules, manufactured by Upjohn US 2 LLC.

Month	Marksans Pharma Share Price Target 2026 (1st Price Target)	Marksans Pharma Share Price Target 2026 (2nd Price target)
January	₹270.16	₹277.85
February	₹274.38	₹279.40
March	₹254.51	₹263.75
April	₹261.90	₹268.03
May	₹265.09	₹273.68
June	₹270.16	₹276.91
July	₹274.82	₹284.65
August	₹280.50	₹287.39
September	₹285.19	₹290.72
October	₹289.64	₹296.37
November	₹295.37	₹308.19
December	₹306.53	₹316.64

Marksans Pharma Share Price Target 2028

Marksans Pharma Share Price Target forecast for 2028 may vary from ₹361.51 to ₹406.92.

Influencing Key Factors For Marksans Pharma Share Price Target 2028

• Increase Presence In Europe
• The company expands its presence in Europe, targeting other key markets besides the UK, such as Germany, where softgels as well as other pipeline products have a good market potential.
• Inorganic Growth Strategies
• The company’s initiatives have already been taken in this direction with the acquisitions of Bell’s, Relonchem & Nova. The company’s leveraging of manufacturing and R&D competencies in India (Low-cost) is also growing. The company’s out-licensing ANDAs to increase market penetration.
• Softgels Opportunity
• Marksans Pharma Limited is currently one of the few active Indian firms focused on the Softgel segment. The company also focused on Softgels, intending to build a differentiated set of offerings in the crowded generics market. The company filed SGC products in all major markets, including the USA, the UK, Europe, Canada, Australia & Russia. The company’s Goa SGC facility has various global regulatory approvals from TGA, UKMHRA, etc.

Month	Marksans Pharma Share Price Target 2028 (1st Price Target)	Marksans Pharma Share Price Target 2028 (2nd Price target)
January	₹361.51	₹369.06
February	₹368.17	₹375.29
March	₹346.35	₹350.64
April	₹348.11	₹357.86
May	₹355.23	₹364.68
June	₹360.02	₹370.37
July	₹368.77	₹375.32
August	₹373.82	₹381.61
September	₹379.65	₹386.95
October	₹384.84	₹390.28
November	₹388.92	₹394.85
December	₹391.88	₹406.92

Marksans Pharma Share Price Target 2030

Marksans Pharma Share Price Target forecast for 2030 may vary from ₹448.26 to ₹490.38.

Influencing Key Factors For Marksans Pharma Share Price Target 2030

• Manufacturing Facilities
• The US pharmaceuticals market plays a dominant role in global sales, and the company’s manufacturing facility is suitably located to cater to this demand. Spread over an area of 7000 square meters, this facility manufactures the company’s ‘Made in the USA’ product lines. Building on the company’s promise to supply diverse healthcare products, the company has added incremental packaging lines. The facility manufactures 6 billion tablets and hard capsules per annum.
• About Marksans Pharma CRAMS
• Marksans Pharma has alliances with the top MNC generic companies for contract manufacturing of 30 generic products for the European markets. The company plans to enhance its product portfolio with the addition of 12-13 products every year. Offering CRAMS for existing and emerging markets is envisaged as one of the major drivers and revenue earners for the company.
• FDI Policy
• 100% Foreign Direct Investment (FDI) is allowed under the automatic route for greenfield projects. The Government may incorporate appropriate conditions under which FDI is permitted under the Government route. The Government may incorporate appropriate conditions for FDI in brownfield cases at the time of granting approvals.

Year	Marksans Pharma Share Price Target 2030
1st Price Target	₹448.26
2nd Price Target	₹490.38

Marksans Pharma Share Price Target 2035

Marksans Pharma Share Price Target forecast for 2035 may vary from ₹701.39 to ₹742.67.

Influencing Key Factors For Marksans Pharma Share Price Target 2035

• Investment Opportunities
• India is expected to be the third-largest global market for active pharmaceutical ingredients by 2016, with a 7.2% increase in market share. Indian pharma companies registered 49% of the overall DMF field in the US in the year 2012.
• India is the largest exporter of formulations with a 14% market share and ranks 12th in the world in terms of export value. Double-digit growth is expected over the last 5 years.
• Financial Support
• The threshold limit for applicability of transfer pricing regulations to specific domestic transactions increased from INR 0.05 billion to INR 0.2 billion. The rate of income tax on royalties and fees for technical services has been reduced from 25% to 10% to facilitate technology inflow. The time limit for taking CENVAT credit on inputs and input services has been increased from six months to one year.

Year	Marksans Pharma Share Price Target 2035
1st Price Target	₹701.39
2nd Price Target	₹742.67

Also Read – Torrent Pharmaceuticals Share Price Target

Peer Company Of Marksans Pharma Limited

Company Name	Market Cap (Crore)
Abbott India	₹65,487.36
Advanced Enzyme	₹3,252.96
Ajanta Pharma	₹32,182.39
Alembic Pharma	₹19,089.63
Alkem Lab	₹63,194.28
AstraZeneca	₹19,930.00
Aurobindo Pharma	₹69,490.01

Discussion About Shareholding Pattern Of Marksans Pharma Limited

Marksans Pharma Limited mainly has four types of shareholding patterns, such as promoter holding, public holding, DII, and FII. Depending on the shareholding pattern, we can majorly influence the company’s growth.

Investor Type	Percentage
Promoter Holding (Owned by the company’s promoter)	43.20%
Public Holding (Held by the public)	29.20%
FII (Invest by Foreign Institutional Investor)	23.10%
DII (Invest money by Domestic Institutional Investor)	4.50%

The Last Few Years’ Share Price Updation Of Marksans Pharma Share

Marksans Pharma Share always gives good returns to investors, which is described in the portion below.

• The last 1 month’s share growth was +29.37 (13.60%).
• The last 6 months’ share growth was -70.15 (-22.23%).
• The last 1 year’s share growth was +80.65 (48.95%).
• The last 5 years’ share growth was +222.70 (981.06%).
• The maximum share growth was +242.80 (9,338.46%).

• Marksans Pharma share price return percentage was 14.92% in the last 1 month.
• The last 3 months’ share price return percentage is 9.15%.
• The last 1 year’s share price return percentage is 45.93%.
• The last 3 years’ share price return percentage is 400.85%.
• The last 5 years’ share price return percentage is 1155.32%.

What Is The Expert Advice About The Investment In Marksans Pharma Share

Positive Sides

• The company is virtually debt-free and has a healthy interest cover ratio of 175.02.
• The company has a healthy liquidity position with a current ratio of 3.26.
• In the last 3 years, the company has been maintaining a good ROCE ratio, which is 16.34%.

Negative Sides

• In the last 3 years, the company has a poor revenue growth, which was 13.02%.
• In the last 3 year’s the company has a poor profit growth, which was 11.37%.
• The company has a high PE ratio of 60.24.
• The company has a trading high EBITDA of 40.12.

Risk Factors Of Marksans Pharma Limited

• Supply Chain Risk
• Disruption in the supply chain for raw materials sourcing or dispatch for exports can impede business operations.
• Technological Risk
• Inability to incorporate the latest technologies into our operations can affect drug output, which might result in severe losses for the company.
• Compliance Risk
• Failure to meet the regulatory or ethical requirements for drug development processes across multiple geographies can impact the company’s business operations.
• Competition Risk
• Intense competition from pharma companies poses a direct threat to the company’s market share and business operations.
• Economic and Growth Risk
• Political and social instability may trigger disruptions within the business environment, impacting the economic and growth prospects of the organization.
• Liquidity Risk
• Sustaining profitability and building a robust balance sheet amid rising input costs is challenging.

Also Read – Cipla Share Price Target

FAQ

Conclusion

This website is written to help the investor gain some basic knowledge about the market strategy of Marksans Pharma Share. For making this blog, we take consultation from experts and research the company. It is expected that the Marksans Pharma Share Price Target will be a good choice to invest in on a long-term basis. The demand for the pharmaceutical sector in India and outside of the country always increases, as a result of which the company and its share may increase rapidly.

We try to give an in-depth idea about the share. If you think it is helpful to you, you can share it. If you have any questions, please let us know through the comment box. We will try to reply to your questions and solve your problem. Thanks for visiting this website and thanks for being with us.

Disclaimer – We are not SEBI-registered advisors. A financial market is always risky to anyone. This website is only for training and educational purposes. So, before investing, we are requested to discuss certified expertise. We will not be responsible for anyone’s profit or loss.